FOR INVESTORS Press releases Choose a page Overview Press Releases Events Financial Info Stock Governance FAQs Year All202620252024202320222021202020192018201620152014 June 11, 2026 Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy June 8, 2026 Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology May 14, 2026 Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting May 13, 2026 Nurix Therapeutics to Participate in Upcoming Investor Conferences May 12, 2026 Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress April 22, 2026 Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 April 8, 2026 Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update April 7, 2026 Nurix Therapeutics to Participate in Upcoming Investor Conference March 23, 2026 Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting January 28, 2026 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update Print Page Contact IR RSS Email Alerts
Year All202620252024202320222021202020192018201620152014 June 11, 2026 Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy June 8, 2026 Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology May 14, 2026 Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting May 13, 2026 Nurix Therapeutics to Participate in Upcoming Investor Conferences May 12, 2026 Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress April 22, 2026 Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 April 8, 2026 Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update April 7, 2026 Nurix Therapeutics to Participate in Upcoming Investor Conference March 23, 2026 Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting January 28, 2026 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
June 11, 2026 Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
June 8, 2026 Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
May 14, 2026 Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
May 12, 2026 Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
April 22, 2026 Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
April 8, 2026 Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
March 23, 2026 Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
January 28, 2026 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
